Patents by Inventor Jacques Mallet

Jacques Mallet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT VIRUSES CODING FOR A GLUTAMATE DECARBOXYLASE (GAD) ACTIVITY
    Publication number: 20020028212
    Abstract: Recombinant viruses comprising a heterologous DNA sequence coding for a protein having glutamate decarboxylase (GAD) activity, preparation thereof, and therapeutic use thereof, in particular for treating and/or preventing degenerative neurological diseases.
    Type: Application
    Filed: November 5, 1996
    Publication date: March 7, 2002
    Inventors: MARIE-CLAUDE GEOFFROY, PHILIPPE HORELLOU, JEAN-FRANCOIS JULIEN, JACQUES MALLET, MICHEL PERRICAUDET, JEAN-JACQUES ROBERT, EMMANUELLE VIGNE, ALEXIS BEMELMANS
  • GENETICALLY-MODIFIED NEURAL PROGENITORS AND USES THEREOF
    Publication number: 20020006660
    Abstract: The invention concerns human neural progenitor cells containing introduced genetic material encoding a product of interest, and their use for the treatment of neurodegenerative diseases.
    Type: Application
    Filed: February 28, 1997
    Publication date: January 17, 2002
    Applicant: Rhone-Poulenc Rorer, S.A.
    Inventors: OLIVIER SABATE, PHILIPPE HORELLOU, MARIE-HELENE BUC-CARON, JACQUES MALLET
  • ADENOVIRUS COMPRISING A GENE CODING FOR GLUTATHIONE PEROXIDASE
    Publication number: 20010029249
    Abstract: The present invention relates to a defective adenovirus comprising at least a DNA sequence coding for all or an active part of glutathione peroxidase or a derivative thereof. It also relates to their utilisation in therapy and to the corresponding pharmaceutical compositions.
    Type: Application
    Filed: May 1, 1997
    Publication date: October 11, 2001
    Inventors: MARTINE BARKATS, JACQUES MALLET, FREDERIC REVAH
  • Recombinant adenoviruses coding for glial-derived neurotrophic factor (GDNF)
    Patent number: 6245330
    Abstract: Recombinant adenoviruses comprising a heterologous DNA sequence coding for glial-derived neurotrophic growth factor (GDNF) are provided. The recombinant adenoviruses are useful in a method of expressing GDNF in a cell, wherein the cell is present in a mammal suffering from Parkinson's disease, comprising infecting said cell with a replication-defective recombinant adenovirus comprising a DNA sequence encoding GDNF operably linked to a promoter by administering the adenovirus into cells of the central nervous system. The recombinant adenoviruses of the invention are also useful in a method of treating Parkinson's disease comprising administering into cells of the central nervous system of a mammal suffering therefrom a replication defective recombinant adenovirus comprising ITRs, an encapsidation sequence and a DNA sequence encoding GDNF operably linked to a promoter, wherein the adenovirus E1 gene is non-functional and GDNF is expressed at a level that provides a therapeutic effect.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: June 12, 2001
    Assignee: Aventis Pharma S.A.
    Inventors: Philippe Horellou, Jacques Mallet, Michel Perricaudet, Frédéric Revah, Emmanuelle Vigne
  • Recombinant expression of the rat vesicular acetylcholine transporter
    Patent number: 6235497
    Abstract: A nucleic sequence coding for a protein involved in the vesicular transport of acetylcholine, the corresponding protein and the promoter sequences implicated in expressing said protein are disclosed. The invention also discloses expression vectors containing said sequence and the therapeutic use of said sequence or said vectors.
    Type: Grant
    Filed: April 21, 1997
    Date of Patent: May 22, 2001
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Stéphane Bejanin, Sylvie Berrard, Riccardo Cervini, Jacques Mallet
  • Method for diagnosing schizophrenia
    Patent number: 6210879
    Abstract: The present invention relates to a method for diagnosing schizophrenia, said method being based on the detection in vitro of the presence of the allele Ep of the microsatellite HUNTH01 in the gene TH. The invention also relates to the primers used for implementing said method.
    Type: Grant
    Filed: December 22, 1997
    Date of Patent: April 3, 2001
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Rolando Meloni, Claudine Laurent, Jacques Mallet
  • Pharmaceutical compositions and their use, namely for the treatment of neurodegenerative diseases
    Patent number: 6140112
    Abstract: The present invention pertains to the use of compounds affecting the activity of transcription factors for the preparation of a pharmaceutical composition for the treatment of neurodegenerative diseases.
    Type: Grant
    Filed: April 25, 1996
    Date of Patent: October 31, 2000
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Jacques Mallet, Frederic Revah, Jean-Jacques Robert
  • Polypeptides having NMDA receptor activity, nucleic acids encoding those polypeptides and applications
    Patent number: 5648259
    Abstract: The present invention concerns novel polypeptides having NMDA receptor activity and genetic material permitting their expression. It also concerns a method for demonstrating and isolating ligands and/or modulators of the activity of these polypeptides and their utilization as drugs.
    Type: Grant
    Filed: January 27, 1995
    Date of Patent: July 15, 1997
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Jacques Mallet, Tania Smirnova